Skip to main content

Articles

Page 2 of 16

  1. The Hox transcript antisense intergenic RNA (HOTAIR) has been identified as a tumor gene, and its expression in HCC is significantly increased. HOTAIR is associated with the proliferation, invasion, metastasis...

    Authors: Bing-rong Wang, Dong-xia Chu, Mei-yu Cheng, Yu Jin, Hao-ge Luo and Na Li
    Citation: Hereditary Cancer in Clinical Practice 2022 20:4
  2. Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art kno...

    Authors: Jelena Maksimenko, Arvīds Irmejs and Jānis Gardovskis
    Citation: Hereditary Cancer in Clinical Practice 2022 20:3
  3. Juvenile polyposis syndrome (JPS), has diverse phenotypes. Aim: To assess mutation rate, clinical features and genotype-phenotype correlation among Israeli JPS kindreds from different ethnicities.

    Authors: Lior Haim Katz, Rachel Gingold-Belfer, Elez Vainer, Shani Hegger, Ido Laish, Estela Derazne, Ilana Weintraub, Gili Reznick-Levi, Yael Goldberg, Zohar Levi, Shlomi Cohen and Elizabeth E. Half
    Citation: Hereditary Cancer in Clinical Practice 2022 20:2
  4. The role of HOXB13 in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of HOXB13 p.G84E mutation in bladder and kidney cancer patients from Poland.

    Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek and Jan Lubiński
    Citation: Hereditary Cancer in Clinical Practice 2022 20:1
  5. The data on prevalence and clinical relevance of TP53 germline mutations in early onset Middle-Eastern breast cancer (BC) is limited.

    Authors: Abdul Khalid Siraj, Tariq Masoodi, Rong Bu, Sandeep Kumar Parvathareddy, Kaleem Iqbal, Saud Azam, Maha Al-Rasheed, Dahish Ajarim, Asma Tulbah, Fouad Al-Dayel and Khawla Sami Al-Kuraya
    Citation: Hereditary Cancer in Clinical Practice 2021 19:49
  6. RAD51D (RAD51 paralog D) is an intermediate cancer susceptibility gene for primary ovarian cancer, including fallopian tube and peritoneal carcinomas and breast cancer. Although gynecological non-epithelial tumor...

    Authors: Mashu Futagawa, Hideki Yamamoto, Mariko Kochi, Yusaku Urakawa, Reimi Sogawa, Fumino Kato, Mika Okazawa-Sakai, Daisuke Ennishi, Katsunori Shinozaki, Hirofumi Inoue, Hiroyuki Yanai and Akira Hirasawa
    Citation: Hereditary Cancer in Clinical Practice 2021 19:48
  7. Multiple primary cancers, defined as three or more primary tumours, are rare, and there are few genetic studies concerning them. There is a need for increased knowledge on the heritability of multiple primary ...

    Authors: Karin Wallander, Håkan Thonberg, Daniel Nilsson and Emma Tham
    Citation: Hereditary Cancer in Clinical Practice 2021 19:46

    The Correction to this article has been published in Hereditary Cancer in Clinical Practice 2021 19:47

  8. The BRCA 1 and BRCA 2 genes are associated with an inherited susceptibility to breast cancer with a cumulative risk of 60% in BRCA 1 mutation carriers and of 30% in BRCA 2 mutation carriers. Several lifestyle ...

    Authors: A. Daniele, R. Divella, B. Pilato, S. Tommasi, P. Pasanisi, M. Patruno, M. Digennaro, C. Minoia, M. Dellino, S. Pisconti, P. Casamassima, E. Savino and A. V. Paradiso
    Citation: Hereditary Cancer in Clinical Practice 2021 19:45
  9. Osteosarcoma is a highly malignant tumour associated with numerous and complex genetic alterations like copy number alterations. Recent whole genome studies revealed distinct mutations in several candidate onc...

    Authors: Alexander Puzik, Markus Uhl, Juri Ruf, Tilmann Schumacher and Udo Kontny
    Citation: Hereditary Cancer in Clinical Practice 2021 19:44
  10. A diagnosis of suspected Lynch syndrome (SLS) is given when a tumour displays characteristics consistent with Lynch syndrome (LS), but no germline pathogenic variant is identified. This inconclusive diagnosis ...

    Authors: Nicole den Elzen, Sharelle L. Joseland, Sibel Saya, Sowmya Jonnagadla, Joanne Isbister, Ingrid Winship and Daniel D. Buchanan
    Citation: Hereditary Cancer in Clinical Practice 2021 19:43
  11. A small but important proportion of patients (4–10 %) with AML have germline mutations. They can cause the development of AML at an earlier age, confer a higher risk of relapse or predispose to secondary leuke...

    Authors: Aneta Bąk, Katarzyna Skonieczka, Anna Jaśkowiec, Anna Junkiert-Czarnecka, Marta Heise, Maria Pilarska-Deltow, Stanisław Potoczek, Maria Czyżewska and Olga Haus
    Citation: Hereditary Cancer in Clinical Practice 2021 19:42
  12. Hereditary Polyposis Syndromes are a group of rare, inherited syndromes characterized by the presence of histopathologically specific or numerous intestinal polyps and an increased risk of cancer. Some polypos...

    Authors: Anne Marie Jelsig, John Gásdal Karstensen, Niels Jespersen, Zohreh Ketabi, Charlotte Lautrup, Karina Rønlund, Lone Sunde, Karin Wadt, Ole Thorlacius-Ussing and Niels Qvist
    Citation: Hereditary Cancer in Clinical Practice 2021 19:41
  13. Consensus and evidence suggest that cascade testing is critical to achieve the promise of cancer genetic testing. However, barriers to cascade testing include effective family communication of genetic risk inf...

    Authors: Suzanne C. O’Neill, Jada G. Hamilton, Claire C. Conley, Beth N. Peshkin, Rosalba Sacca, Glynnis A. McDonnell, Claudine Isaacs, Mark E. Robson and Kenneth P. Tercyak
    Citation: Hereditary Cancer in Clinical Practice 2021 19:40
  14. The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2.

    Authors: Michelle Jacobson, Nadia Coakley, Marcus Bernardini, Kelly-Ann Branco, Laurie Elit, Sarah Ferguson and Raymond Kim
    Citation: Hereditary Cancer in Clinical Practice 2021 19:39
  15. Due to increased risk of endometrial and ovarian cancer, women belonging to known Lynch Syndrome (LS) families are recommended to undergo germline testing. Current practice in Finland is to offer counselling t...

    Authors: Mari Kalamo, Johanna Mäenpää, Toni Seppälä, Jukka-Pekka Mecklin, Kirsi Pylvänäinen and Synnöve Staff
    Citation: Hereditary Cancer in Clinical Practice 2021 19:38
  16. Authors: Krithika Murali, Tanya M. Dwarte, Mehrdad Nikfarjam, Katherine M. Tucker, Rhys B. Vaughan, Marios Efthymiou, Allison Collins, Allan D. Spigelman, Lucinda Salmon, Amber L. Johns, David B. Williams, Martin B. Delatycki, Thomas John and Alina Stoita
    Citation: Hereditary Cancer in Clinical Practice 2021 19:37

    The original article was published in Hereditary Cancer in Clinical Practice 2021 19:33

  17. Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-rib...

    Authors: Evgeny N. Imyanitov
    Citation: Hereditary Cancer in Clinical Practice 2021 19:36
  18. Nearly 56% of at-risk carriers are not identified and missed as a result of the current family-history (FH) screening for genetic testing. The present study aims to review the economic evaluation studies on BR...

    Authors: Zahra Meshkani, Ali Aboutorabi, Najmeh Moradi, Mostafa Langarizadeh and Ali Ghanbari Motlagh
    Citation: Hereditary Cancer in Clinical Practice 2021 19:35
  19. Muir–Torre syndrome (MTS), which accounts for a small subset (1–3 %) of Lynch syndrome (LS), is an autosomal dominant genetic disorder characterized by sebaceous gland or keratoacanthoma associated with viscer...

    Authors: Makoto Nakagawa, Eisuke Kobayashi, Masayoshi Yamada, Tomoko Watanabe, Makoto Hirata, Noriko Tanabe, Mineko Ushiama, Hiromi Sakamoto, Chiaki Sato, Taisuke Mori, Akihiko Yoshida, Teruhiko Yoshida, Kokichi Sugano and Akira Kawai
    Citation: Hereditary Cancer in Clinical Practice 2021 19:34
  20. The Australian Pancreatic Cancer Screening Program (APCSP) offers endoscopic ultrasound surveillance for individuals at increased risk of pancreatic ductal adenocarcinoma (PDAC) with all participants requiring...

    Authors: Krithika Murali, Tanya M. Dwarte, Mehrdad Nikfarjam, Katherine M. Tucker, Rhys B. Vaughan, Marios Efthymiou, Allison Collins, Allan D. Spigelman, Lucinda Salmon, Amber L. Johns, David B. Williams, Martin B. Delatycki, Thomas John and Alina Stoita
    Citation: Hereditary Cancer in Clinical Practice 2021 19:33

    The Correction to this article has been published in Hereditary Cancer in Clinical Practice 2021 19:37

  21. The microphthalmia-associated transcription factor gene (MITF) belongs to the MYC supergene family and plays an important role in melanocytes’ homeostasis. Individuals harboring MITF germline pathogenic variants ...

    Authors: Leandro Jonata Carvalho Oliveira, Aline Bobato Lara Gongora, Fabiola Ambrosio Silveira Lima, Felipe Sales Nogueira Amorim Canedo, Carla Vanessa Quirino, Janina Pontes Pisani, Maria Isabel Achatz and Benedito Mauro Rossi
    Citation: Hereditary Cancer in Clinical Practice 2021 19:32
  22. Family health history (FHx) is an effective tool for identifying patients at risk of hereditary cancer. Hereditary cancer clinical practice guidelines (CPG) contain criteria used to evaluate FHx and to make re...

    Authors: Jordon B. Ritchie, Cecelia Bellcross, Caitlin G. Allen, Lewis Frey, Heath Morrison, Joshua D. Schiffman and Brandon M. Welch
    Citation: Hereditary Cancer in Clinical Practice 2021 19:31
  23. Aim of the study is to evaluate the role of ultrasound guided fine needle aspiration cytology (FNAC) in the restaging of node positive breast cancer after preoperative systemic therapy (PST).

    Authors: Baiba Līcīte, Arvīds Irmejs, Jeļena Maksimenko, Pēteris Loža, Genādijs Trofimovičs, Edvīns Miklaševičs, Jurijs Nazarovs, Māra Romanovska, Justīne Deičmane, Reinis Irmejs, Gunta Purkalne and Jānis Gardovskis
    Citation: Hereditary Cancer in Clinical Practice 2021 19:30
  24. Although extended colectomy (EC) was recommended for HNPCC patients, previous studies did not show significantly improved overall survival. Immunohistochemical (IHC) stain of mismatch repair (MMR) gene protein...

    Authors: Chun-Kai Liao, Yueh-Chen Lin, Yu-Jen Hsu, Yih-Jong Chern, Jeng-Fu You and Jy-Ming Chiang
    Citation: Hereditary Cancer in Clinical Practice 2021 19:29
  25. Endometrial cancer is often the sentinel cancer in women with Lynch syndrome, among which endometrioid endometrial cancer is the most common. We found a Korean case of uterine carcinosarcoma associated with Ly...

    Authors: Youn-Joon Jung, Hye Ryoun Kim, Mi Kyung Kim and Eun-Ju Lee
    Citation: Hereditary Cancer in Clinical Practice 2021 19:28
  26. DNA mismatch repair (MMR) genes play an important role in maintaining genome stability. Germline mutations in MMR genes disrupt the mismatch repair function and cause genome instability. Carriers with MMR germ...

    Authors: Min Zhang and Tianhui Chen
    Citation: Hereditary Cancer in Clinical Practice 2021 19:26

    The Correction to this article has been published in Hereditary Cancer in Clinical Practice 2021 19:27

  27. Familial adenomatous polyposis (FAP) is an autosomal dominant condition that predisposes patients to colorectal cancer. FAP is the result of a loss of APC function due to germline pathogenic variants disruptin...

    Authors: T Connor, M McPhillips, M Hipwell, A Ziolkowski, C Oldmeadow, M Clapham, PG Pockney, E Lis, T Banasiewicz, A Pławski and RJ Scott
    Citation: Hereditary Cancer in Clinical Practice 2021 19:25
  28. This nationwide study assessed the impact of nationally agreed cancer genetics guidelines on use of BRCA1/2 germline testing, risk management advice given by health professionals to women with pathogenic BRCA1/2 ...

    Authors: Bettina Meiser, Rajneesh Kaur, April Morrow, Michelle Peate, W. K. Tim Wong, Emily McPike, Elisa Cops, Cassandra Nichols, Rachel Austin, Miriam Fine, Letitia Thrupp, Robyn Ward, Finlay Macrae, Janet E. Hiller, Alison H. Trainer and Gillian Mitchell
    Citation: Hereditary Cancer in Clinical Practice 2021 19:24
  29. We have previously reported a family with a suspected autosomal dominant rectal and gastric cancer syndrome without any obvious causative genetic variant. Here, we focused the study on a potentially isolated r...

    Authors: Karin Wallander, Jessada Thutkawkorapin, Ellika Sahlin, Annika Lindblom and Kristina Lagerstedt-Robinson
    Citation: Hereditary Cancer in Clinical Practice 2021 19:23
  30. Although CDKN2A is well-known as a susceptibility gene for melanoma and pancreatic cancer, germline variants have also been anecdotally associated with a broader range of neoplasms including neural system tumors,...

    Authors: Sock Hoai Chan, Jianbang Chiang and Joanne Ngeow
    Citation: Hereditary Cancer in Clinical Practice 2021 19:21
  31. The presence of hereditary cancer syndromes in cancer patients can have an impact on current clinical care and post-treatment prevention and surveillance measures. Several barriers inhibit identification of he...

    Authors: Si Ming Fung, R. Ryanne Wu, Rachel A. Myers, Jasper Goh, Geoffrey S. Ginsburg, David Matchar, Lori A. Orlando and Joanne Ngeow
    Citation: Hereditary Cancer in Clinical Practice 2021 19:20
  32. Guidelines for referral to cancer genetics service for women diagnosed with triple negative breast cancer have changed over time. This study was conducted to assess the changing referral patterns and outcomes ...

    Authors: Lucie G. Hallenstein, Carol Sorensen, Lorraine Hodgson, Shelly Wen, Justin Westhuyzen, Carmen Hansen, Andrew T. J. Last, Julan V. Amalaseelan, Shehnarz Salindera, William Ross, Allan D. Spigelman, Thomas P. Shakespeare and Noel J. Aherne
    Citation: Hereditary Cancer in Clinical Practice 2021 19:19
  33. Lynch syndrome is caused by germline mutations in the mismatch repair genes and is characterised by a familial accumulation of colorectal and other cancers. Earlier identification of Lynch syndrome patients en...

    Authors: Sophie Walton Bernstedt, Jan Björk, Kaisa Fritzell, Allan D. Spigelman, Erik Björck and Ann-Sofie Backman
    Citation: Hereditary Cancer in Clinical Practice 2021 19:18
  34. Familial clustering of lymphoid and/or hematological malignancies (FHM) provides an opportunity to study the responsible genes. The data is limited in patients with lymphoid and hematological malignancies.

    Authors: Saad Akhtar, M. Shahzad Rauf, Amani Al-Kofide, Mahmoud A. Elshenawy, Ali Hassan Mushtaq and Irfan Maghfoor
    Citation: Hereditary Cancer in Clinical Practice 2021 19:17
  35. The pathogenic BRCA1/2 germline mutations contributed to Hereditary Breast and Ovarian Cancer (HBOC) susceptibility. The features of BRCA1/2 germline mutations in non-small cell lung cancer (NSCLC) have not be...

    Authors: Zheyuan Xu, Yang Wang, Lan Wang, Fengxian Cui, Libin Zhang, Jian Xiong and Hao Peng
    Citation: Hereditary Cancer in Clinical Practice 2021 19:16
  36. In the past two decades, genetic testing for cancer risk assessment has entered mainstream clinical practice due to the availability of low-cost panels of multiple cancer-associated genes. However, the clinica...

    Authors: Christa Slaught, Elizabeth G. Berry, Lindsay Bacik, Alison H. Skalet, George Anadiotis, Therese Tuohy and Sancy A. Leachman
    Citation: Hereditary Cancer in Clinical Practice 2021 19:15
  37. Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade ser...

    Authors: Tatiana V. Gorodnova, Anna P. Sokolenko, Khristina B. Kotiv, Tatiana N. Sokolova, Alexandr O. Ivantsov, Konstantin D. Guseynov, Ekaterina A. Nekrasova, Olga A. Smirnova, Igor V. Berlev and Evgeny N. Imyanitov
    Citation: Hereditary Cancer in Clinical Practice 2021 19:14
  38. Mutations in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Central-Eastern European counties, the founder mutations in the BRCA1 are responsible for a significant proportion ...

    Authors: Alena Savanevich, Olgierd Ashuryk, Cezary Cybulski, Jan Lubiński and Jacek Gronwald
    Citation: Hereditary Cancer in Clinical Practice 2021 19:13
  39. Medulloblastoma is an aggressive brain tumor mostly found in children, few studies on pathogenic germline mutations predisposing this disease was reported.

    Authors: Caiping Ke, Xiaoshun Shi, Allen Menglin Chen, Chaoming Li, Bifeng Jiang, Kailing Huang, Zhouxia Zheng, Yanhui Liu, Zhuona Chen, Yingjun Luo, Huaming Lin and Jiexia Zhang
    Citation: Hereditary Cancer in Clinical Practice 2021 19:12
  40. Several recent studies in the Baltic region have found extended spectrum of pathogenic variants (PV) of the BRCA1/2 genes. The aim of current study is to analyze the spectrum of the BRCA1/2 PV in population of La...

    Authors: P. Loza, A. Irmejs, Z. Daneberga, E. Miklasevics, E. Berga-Svitina, S. Subatniece, J. Maksimenko, G. Trofimovics, E. Tauvena, S. Ukleikins and J. Gardovskis
    Citation: Hereditary Cancer in Clinical Practice 2021 19:11
  41. The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors f...

    Authors: Abhishek Kumar, Nagarajan Paramasivam, Obul Reddy Bandapalli, Matthias Schlesner, Tianhui Chen, Rolf Sijmons, Dagmara Dymerska, Katarzyna Golebiewska, Magdalena Kuswik, Jan Lubinski, Kari Hemminki and Asta Försti
    Citation: Hereditary Cancer in Clinical Practice 2021 19:10
  42. CHEK2 has been recognized as a breast cancer risk gene with moderate effect. Women who have previously tested negative for a BRCA1/2 gene germline pathogenic variant may benefit from additional genetic testing fo...

    Authors: Mary E. Velthuizen, Rob B. van der Luijt, Beja J. de Vries, Marco J. Koudijs, Eveline M. A. Bleiker and Margreet G. E. M. Ausems
    Citation: Hereditary Cancer in Clinical Practice 2021 19:9
  43. 16–25% of colorectal cancers (CRCs) diagnosed under age 50 are associated with hereditary cancer syndromes. Advanced adenomas are considered precursors to CRC. Although polyp removal prevents cancer, polypecto...

    Authors: Swati G. Patel, Heather Hampel, Derek Smith, Dexiang Gao, Myles Cockburn and Fay Kastrinos
    Citation: Hereditary Cancer in Clinical Practice 2021 19:8
  44. Germline DNA mismatch repair (MMR) gene aberrations are associated with colorectal cancer (CRC) predisposition and high tumor mutation burden (TMB-H), with increased likelihood of favorable response to immune ...

    Authors: Tong Xie, Qin Feng, Zhongwu Li, Ming Lu, Jian Li, Analyn Lizaso, Jianxing Xiang, Lu Zhang, Lin Shen and Zhi Peng
    Citation: Hereditary Cancer in Clinical Practice 2021 19:7
  45. The role of PALB2 in carcinogenesis remains to be clarified. Our main goal was to determine the prevalence of PALB2 (509_510delGA and 172_175delTTGT) mutations in bladder and kidney cancer patients from Polish po...

    Authors: Elżbieta Złowocka-Perłowska, Tadeusz Dębniak, Marcin Słojewski, Artur Lemiński, Michał Soczawa, Thierry van de Wetering, Joanna Trubicka, Wojciech Kluźniak, Dominika Wokołorczyk, Cezary Cybulski and Jan Lubiński
    Citation: Hereditary Cancer in Clinical Practice 2021 19:6
  46. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Muhammad Usman Rashid, Noor Muhammad, Faiz Ali Khan, Umara Shehzad, Humaira Naeemi, Naila Malkani and Ute Hamann
    Citation: Hereditary Cancer in Clinical Practice 2021 19:4

    The original article was published in Hereditary Cancer in Clinical Practice 2020 18:25

Annual Journal Metrics

  • 2022 Citation Impact
    1.7 - 2-year Impact Factor
    2.2 - 5-year Impact Factor
    0.634 - SNIP (Source Normalized Impact per Paper)
    0.526 - SJR (SCImago Journal Rank)

    2022 Speed
    6 days submission to first editorial decision for all manuscripts (Median)
    148 days submission to accept (Median)

    2022 Usage 
    277,857 downloads
    231 Altmetric mentions